AdaptHealth (AHCO) Q3 2024 earnings summary

Executive summary

• Q3 2024 net revenue was $805.9 million, up 0.2% year-over-year, driven by growth in sleep and respiratory categories, offset by declines in diabetes revenue.

• Net income attributable to shareholders was $22.9 million, reversing a net loss of $454.1 million in Q3 2023, which included a $511.9 million goodwill impairment.

• Adjusted EBITDA reached $164.3 million (20.4% margin), up from $161.2 million (20.0% margin) in Q3 2023.

• Free cash flow for Q3 2024 was $84.8 million, outperforming the $30 million target and up from $21.7 million in Q3 2023.

• Leadership and operational restructuring were implemented in the diabetes segment to address underperformance.

Financial highlights

• Sales revenue was $510.7 million, rental revenue $262.3 million, and capitated revenue $32.9 million for Q3 2024.

• Operating income for Q3 2024 was $63.5 million, compared to a loss of $461.0 million in Q3 2023.

• Year-to-date cash flow from operations reached $391.4 million, up from $325.4 million year-over-year.

• Free cash flow for the nine months ended September 30, 2024, was $162.7 million, more than doubling from $76.6 million in 2023.

• Basic and diluted EPS for Q3 2024 were $0.16 and $0.15, respectively, compared to $(3.37) and $(3.43) in Q3 2023.

Outlook and guidance

• Full-year 2024 net revenue guidance lowered to $3.22–$3.26 billion, Adjusted EBITDA to $655–$675 million, reflecting diabetes headwinds.

• Free cash flow guidance raised to $175–$195 million due to positive working capital trends.

• Management expects continued inflationary pressures on materials, labor, and transportation, with mitigation efforts focused on vendor negotiations and technology-driven efficiencies.

• Multi-year net leverage target set at 2.5x, with near-term focus on deleveraging over acquisitions.

• The company believes operating cash flows, existing cash, and available credit will be sufficient to fund operations and growth strategies for at least the next twelve months.